Synthetic peptides derived from the C-Terminal region of Lys49 phospholipase A2 homologues from viperidae snake venoms: Biomimetic activities and potential applications

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3224-3230

  Lomonte, Bruno ^a   Angulo, Yamileth ^a   Moreno, Edgardo ^a,b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b UNIVERSIDAD NACIONAL   (Costa Rica)

Author keywords

Antimicrobial; Antitumor; Biomimetic; Heparin; Phospholipase A2; Snake venom; Synthetic peptides; VEGF

Indexed keywords

AROMATIC AMINO ACID; BACTERIUM LIPOPOLYSACCHARIDE; BATROXOBIN; BOTHROPS ASPER MYOTOXIN II; BOTHROPS ASPER MYOTOXIN II [115-129]; BOTHROPSTOXIN I; HEPARIN; LACTOFERRICIN; LIPOTEICHOIC ACID; LYSINE; LYSINE49 PHOSPHOLIPASE A2; P115 W3 PEPTIDE; PACLITAXEL; PEM 1 PEPTIDE; PEM 10 PEPTIDE; PEM 2 PEPTIDE; PHOSPHOLIPASE A2; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; SNAKE VENOM; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VIPER VENOM;

ALLODYNIA; AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ANTICOAGULATION; ANTIENDOTOXIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPARASITIC ACTIVITY; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BIOMIMETICS; BREAST CANCER; BREAST CARCINOMA; CALCIUM TRANSPORT; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CYTOLYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EDEMA; ENVENOMATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYSIS; HUMAN; HYDROPHOBICITY; HYPERALGESIA; IMMUNOGENICITY; INFLAMMATION; KLEBSIELLA PNEUMONIAE; MELANOMA; MEMBRANE DAMAGE; MITOSIS INHIBITION; MOLECULAR WEIGHT; MUSCLE NECROSIS; MUSCLE TOXICITY; MYELOMA; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA TYPHIMURIUM; SARCOMA; SKELETAL MUSCLE; STAPHYLOCOCCUS AUREUS; T CELL LEUKEMIA; TOXICITY; VIBRIO CHOLERAE;

ANIMALS; BIOMIMETIC MATERIALS; DRUG DESIGN; GROUP II PHOSPHOLIPASES A2; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; PEPTIDES; VIPER VENOMS; VIPERIDAE;

EID: 78649867661     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292456     Document Type: Review

References (83)

1. Fry BG, Scheib H, van der Weerd L, et al. Evolution of an arsenal: structural and functional diversification of the venom system in the advanced snakes (Caenophidia). Mol Cell Proteomics 2008; 7: 215-46.
2. Calvete JJ. Venomics: digging into the evolution of venomous systems and learning to twist nature to fight pathology. J Proteomics 2009; 72: 121-6.
3. 2 enzymes: structure, function, and mechanism. England: John Wiley & Sons 1997; p. 511.
4. 2 enzymes. Toxicon 2003; 42: 827-40.
5. 2 myotoxins and neurotoxins: common aspects of their mechanisms of action. Cell Mol Life Sci 2008; 65: 2897-912.
6. 2. Toxicon 2008; 51: 1520-29.
7. Warrell DA. Snakebite. Lancet 2010; 375: 77-88.
8. 2 - a structural review. Toxicon 1996; 34: 827-41.
9. 2 superfamily and its group numbering system. Biochim Biophys Acta 2006; 1761: 1246-59.
10. 2: biological and membrane-disrupting activities in the absence of catalysis. Biochem J 2002; 362: 89-96.
11. 2 homologue decreases its Ca2+- independent membrane-damaging activity and increases its toxicity. Biochemistry 2007; 46: 12795-809.
12. 2 with lysine in place of aspartate 49. J Biol Chem 1984; 259: 13839-43.
13. 2. J Biol Chem 1986; 261: 4797-804.
14. 2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 2003; 42: 885-901.
15. 2 homologues of snake venoms: biological activities and their possible adaptive roles. Protein Pept Lett 2009; 16: 860-76.
16. 2 myotoxins from Bothrops snake venoms: structure-function relationship. Curr Org Chem 2004; 8: 1677-90.
17. 2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J Biol Chem 1994; 269: 29867-73.
18. 2 from bovine pancreas and Crotalus atrox venom. J Biol Chem 1985; 260: 11627-34.
19. 2 on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells in vitro. Toxicon 1999; 37: 145-58.
20. 2 homologues are reduced, but not abolished, by a pH-induced dissociation. Toxicon 2005; 46: 291-6.
21. 2 myotoxins from crotalid snake venoms. Cell Biochem Funct 2005; 23: 307-13.
22. 2 by scanning alanine mutagenesis. Biochim Biophys Acta 2007; 1768: 1247-57.
23. 2 homologue from the venom of the snake Bothrops asper: evidence of rapid plasma membrane damage and a dual role for extracellular calcium. Toxicology In Vitro 2007; 21: 1382-9.
24. Cintra-Francischinelli M, Pizzo P, Rodrigues-Simioni L, et al. Calcium imaging of muscle cells treated with snake myotoxins reveals toxin synergism and presence of receptors. Cell Mol Life Sci 2009; 66: 1718-28.
25. Lomonte B, Gutiérrez JM. A new muscle damaging toxin, myotoxin II, from the venom of the snake Bothrops asper (terciopelo). Toxicon 1989; 27: 725-33.
26. 2. Arch Biochem Biophys 1991; 284: 352-9.
27. Arni RK, Ward RJ, Gutiérrez JM, Tulinsky A. Structure of a calcium-independent phospholipase-like myotoxic protein from Bothrops asper venom. Acta Cryst D 1995; 51: 311-7.
28. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon 2001; 39: 1587-94.
29. 2 from snake venoms. Toxicon 2003; 42: 307-12.
30. Kini RM, Evans HJ. A common cytolytic region in myotoxins, hemolysins, cardiotoxins, and antibacterial peptides. Int J Pept Prot Res 1989; 34: 277-86.
31. 2 using tryptophan scanning mutagenesis of bothropstoxin-I from Bothrops jararacussu. Biochimie 2008; 90: 1397-406.
32. 2 from Bothrops genus reveal their myotoxic site. J Struct Biol 2009; 167: 106-16.
33. 2) with liposome membranes. Toxicon 2009; 54: 525-30.
34. 2. Prot Pept Lett 2009; 16: 877-86.
35. 2 homologues. Toxicon 2010; 55: 1-11.
36. Cintra-Francischinelli M, Pizzo P, Angulo Y, Gutiérrez JM, Montecucco C, Lomonte B. The C-terminal region of a Lys49 myotoxin mediates Ca2+ influx in C2C12 myotubes. Toxicon 2010; 55: 590-6.
37. 2. J Clin Invest 1996; 97: 250-7.
38. 2. Biochim Biophys Acta 2000; 1488: 71-82.
39. 2. J Biol Chem 2002; 277: 1788-93.
40. 2. Review. Biochim Biophys Acta 2008; 1781: 1-9.
41. 2 from Bothrops asper snake venom: synthetic Lys49 myotoxin II-(115-129)-peptide identifies its bactericidal region. Eur J Biochem 1998; 253: 452-61.
42. 2. J Biol Chem 2002; 277: 5849-57.
43. 2 homologue from Bothrops neuwiedi pauloensis venom. Arch Biochem Biophys 2000; 378: 201-9.
44. 2 from Bothrops pirajai snake venom. Archs Biochem Biophys 2001; 387: 188-96.
45. 2 from snake venoms: effects on catalytic and pharmacological properties. Toxicon 2003; 42: 855-68.
46. 2 homologue from the venom of the snake Bothrops atrox. Toxicon 2004; 44: 91-101.
47. Barbosa PSF, Martins AMC, Havt A, et al. Renal and antibacterial effects induced by myotoxin I and II isolated from Bothrops jararacussu venom. Toxicon 2005; 46: 376-86.
48. 2 from crotalid snake venoms and synthetic peptide variants derived from their C-terminal region. Toxicon 2005; 45: 807-15.
49. 2 from Bothrops jararacussu. Toxicon 2008; 51: 538-46.
50. 2 to LPS and suppression of its effects on mouse macrophages. Toxicon 2007; 50: 914-22.
51. Shlaes DM, Projan SJ, Edwards JE. Antibiotic discovery: state of the state. ASM News 2004; 70: 275-81.
52. Bush K. Why it is important to continue antibacterial drug discovery. ASM News 2004; 70: 282-7.
53. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-23.
54. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
55. Marr AK, Gooderham WJ, Hancock REW. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006; 6: 468-72.
56. 2 expresses enhanced membrane-damaging activities and reproduces its in vivo myotoxic effect. Biochim Biophys Acta 1999; 1461: 19-26.
57. 2. Antimicrob Agents Chemother 2005; 49, 1340-5.
58. Quan B, Ianoul A. UV resonance Raman spectroscopy probes the localization of tryptophan-containing antimicrobial peptides in lipid vesicles. J Raman Spectrosc 2009; 40: 260-3.
59. Won A, Ianoul A. Interactions of antimicrobial peptide from Cterminus of myotoxin II with phospholipid mono- and bilayers. Biochim Biophys Acta 2009; 1788: 2277-83.
60. David SA, Balasubramanian KA, Mathan VI, Balaram P. Analysis of the binding of polymyxin B to endotoxic lipid A and core glycolipid using a fluorescent displacement probe. Biochim Biophys Acta 1992; 1165: 147-52.
61. Gruber A, Mancek M, Wagner H, Kirschning CJ, Jerala R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem 2004; 279: 28475-82.
62. Barquero-Calvo E, Conde-Alvarez R, Chacón-Díaz C, et al. The differential interaction of Brucella and Ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens. PLoS One 2009; 4(6): e5893 doi: 10.1371/journal.pone.0005893.
63. 2-derived synthetic peptide variant upon Candida albicans. Rev Esp Quimioter 2007; 20: 330-333.
64. 2 isolated from Bothrops brazili snake venom and synthetic peptides derived from their C-terminal region: cytotoxic effect on microorganism and tumor cells. Peptides 2008; 29: 1645-56.
65. 2 homologue: an example of function versatility of snake venom proteins. Comp Biochem Physiol C 2006; 142: 371-81.
66. 2 homologues of snake venoms. Cell Biol Int 2007; 31, 263-8.
67. 2-like BthTX-I and a synthetic peptide derived from its C-terminal region. Biologicals 2009; 37: 222-9.
68. Papo N, Shai, Y. New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003; 42: 9346-54.
69. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003; 278: 21018-23.
70. Papo N, Braunstein A, Eshhar Z, Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostatespecific antigen secretion. Cancer Res 2004; 64: 5779-86.
71. Xu N, Wang YS, Pan W, et al. Human α-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther 2008; 7: 1588-97.
72. 2. J Biol Chem 2005; 280: 29989-92.
73. 2 homologue binds to vascular endothelial growth factor receptor-2 via C-terminal loop region. Biochem J 2008; 411: 515-22.
74. Melo PA, Homsi-Brandeburgo MI, Giglio JR, Suarez-Kurtz G. Antagonism of the myotoxic effect of Bothrops jararacussu venom and bothropstoxin by polyanions. Toxicon 1993; 31: 285-91.
75. 2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/ heparan sulfate family. Biochem Pharmacol 1994; 47: 1509-18.
76. 2. Biochem Pharmacol 2003; 66: 1993-2000.
77. 2s with heparin neutralizing properties from Bothrops moojeni snake venom. Toxicon 2010; in press.
78. 2 activity based on ligand-induced conformational change. J Biol Chem 2005; 280: 7326-35.
79. 2 from the venom of the cottonmouth snake at 2.0-Å resolution. J Biol Chem 1990; 265: 17649-58.
80. 2 homologues. Toxicon 2007; 49: 378-87.
81. 2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 2005; 11(10): 1301-12.
82. Yamazaki Y, Morita T. Snake venom components affecting blood coagulation and the vascular system: structural similarities and marked diversity. Curr Pharm Des 2007; 13(28): 2872-86.
83. Zaiou M, Benachour H, Marteau JB, Visvikis-Siest S, Siest G. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Curr Pharm Des 2009; 15(27): 3193-206.